Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOXF1 mRNA nanoparticles
- Development stage
- Preclinical
- Lead developer
- University of Arizona
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FOXF1 mRNA nanoparticles are a precision gene therapy designed to treat pediatric acute respiratory distress syndrome (PARDS) and acute lung injury (ALI). The therapy utilizes pulmonary endothelial-targeted nanoparticles to deliver stabilized mRNA encoding the FOXF1 transcription factor directly to the lung vasculature. FOXF1 is a critical regulator of lung development and endothelial stability; its expression is significantly reduced during systemic sepsis and inflammatory lung injury. By restoring FOXF1 levels, the treatment promotes the transcriptional activation of the anti-apoptotic gene Bcl2, thereby reducing endothelial cell apoptosis, enhancing vascular barrier function, and mitigating pulmonary leakage. This approach is being developed by researchers at the University of Arizona and Phoenix Children’s Hospital.
- Other names
- FOXF1 mRNA NPFOXF-1 mRNA NPFOXF 1 mRNA NPpulmonary endothelial-targeted nanoparticle delivery of FOXF1 mRNA
02
Targets
FOXO1 (Forkhead box protein O1)Fanconi anemia DNA repair complex proteinsFOX (FOX (Forkhead box) transcription factors)
Beyond the preview
Go deeper on FOXF1 mRNA nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOXF1 mRNA nanoparticles.